Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma and Cancer-Testis Antigen (CTA) Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RBMY1D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RBMY1D Recombinant Protein (RRM Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for RNA-binding assays. |
View RBMY1D Products |
| Gene Delivery | RBMY1D Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View RBMY1D Products |
| Benchmark Ab | Anti-RBMY1D Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View RBMY1D Products |
| Validator | RBMY1D siRNA Set For knockdown verification and functional rescue assays. |
View RBMY1D Products |
| Related Target A | RBMX X-linked homolog of RBMY. Critical counter-screening target to ensure drug selectivity and avoid systemic toxicity. |
View RBMX Products |
| Related Target B | GPC3 Oncofetal antigen co-expressed in hepatocellular carcinoma (HCC) for potential bispecific or combination strategies. |
View GPC3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High sequence homology with RBMX and RBMY family members | Human RBMY1D and RBMX ortholog proteins available with >95% purity for robust selectivity profiling. |
| Maintaining RNA-binding domain conformation | Sequence-verified, endotoxin-controlled RRM domain proteins with precise theoretical MW and high conformational stability. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and high-affinity detection reagents included. |
| False Positives | Validated siRNA included for specificity and target-knockdown validation. |
Live RBMY1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RBMY1D therapeutics is intensifying, with major players shifting focus from traditional oncology targets to male-biased cancer-testis antigens (CTAs). As first-generation RNA-targeted therapies and small-molecule splicing modulators reach the clinic, the next wave of R&D is targeting RBMY1D for its specific overexpression in male hepatocellular carcinoma (HCC) patients.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (RRM Inhibitors) | Academic Institutes, Biotech Startups | Hepatocellular Carcinoma (HCC) | Selectivity Assay (Need Mutant vs WT RBMY1D and RBMX Proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory Liver Cancers | Ubiquitination & Degradation Assays (Need Stable Cell Lines via Lentivirus) |
| Immunotherapy (TCR-T / CTA Vaccines) | Cell Therapy Developers | Advanced Solid Tumors (Male-biased) | Antigen Presentation & Binding Assays (Need High-Purity Recombinant Proteins) |